Heartburn Relief is the Major Unmet Need for Drug Development in Gastroesophageal Reflux Disease: Threshold Value Analysis

Heartburn symptoms contribute to healthcare-seeking among patients with gastroesophageal reflux disease (GERD). Despite clinical guidance, management is often dictated by insurance restrictions. Several potassium-competitive acid blockers (PCAB) are under development as a new class of therapy. We performed economic analyses to align GERD drug development with the needs of gastroenterologists, insurers and patients in a value-based environment.

Source: Clinical Gastroenterology and Hepatology - February 15, 2024 Category: Gastroenterology Authors: Eric D. Shah, Michael A. Curley, Amit Patel, Wai-Kit Lo, Walter W. Chan Source Type: research